Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SLXN
stocks logo

SLXN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast SLXN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLXN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast SLXN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLXN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.167
sliders
Low
12.00
Averages
12.00
High
12.00
Current: 3.167
sliders
Low
12.00
Averages
12.00
High
12.00
Maxim Group
Naz Rahman
Strong Buy
Maintains
$9 → $5
2025-03-20
Reason
Maxim Group
Naz Rahman
Price Target
$9 → $5
2025-03-20
Maintains
Strong Buy
Reason
Maxim lowered the firm's price target on Silexion Therapeutics to $5 from $9 and keeps a Buy rating on the shares after its Q4 results. The company is progressing with its SIL-204, an updated formulation of its prior LODER therapy, a KRAS targeting siRNA therapy for treating non-resectable, locally advanced pancreatic cancer, though the firm is reducing its price target due to the additional dilution from the recent capital raise and warrant exercises, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Silexion Therapeutics Corp (SLXN.O) is -0.38, compared to its 5-year average forward P/E of -0.13. For a more detailed relative valuation and DCF analysis to assess Silexion Therapeutics Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.13
Current PE
-0.38
Overvalued PE
0.17
Undervalued PE
-0.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SLXN News & Events

Events Timeline

(ET)
2025-12-02
08:10:00
Silexion Receives Regulatory Guidance for Phase 2/3 Trial of SIL204
select
2025-11-25 (ET)
2025-11-25
09:16:01
Silexion Therapeutics finishes toxicology studies for SIL204
select
2025-11-12 (ET)
2025-11-12
09:02:09
Silexion Therapeutics announces Q3 EPS of $2.88 compared to $274.25 in the previous year.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-26NASDAQ.COM
Silexion Finishes Toxicology Studies for SIL204; Phase 2/3 Trial for Pancreatic Cancer Set to Start in Q2

  • SIL204 Development: Silexion Therapeutics has completed toxicology studies for SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes in pancreatic cancer, showing no systemic organ toxicity.

  • Therapeutic Potential: SIL204 has demonstrated significant inhibition of cancer cell growth in preclinical models and positive anti-tumor activity in pancreatic cancer, paving the way for regulatory submissions in Israel and Germany.

  • Clinical Trial Plans: The therapy is set to progress to a Phase 2/3 trial in Q2 2026, utilizing a unique regimen that combines intratumoral and systemic administration to evaluate safety and efficacy in patients with locally advanced pancreatic cancer.

  • Stock Performance: Silexion's stock has fluctuated between $2.13 and $63.45 over the past year, closing at $2.44, reflecting a 13.48% increase in recent trading.

[object Object]
Preview
9.0
11-25Newsfilter
Silexion Completes Toxicology Studies for SIL204, Plans Phase 2/3 Trial in 2026
  • Successful Toxicology Studies: Silexion has completed dual-species toxicology studies for SIL204, confirming no systemic organ toxicity, which lays the groundwork for planned regulatory submissions in Israel and Germany, potentially accelerating clinical trial progress.
  • Clinical Trial Timeline: The company is on track to initiate a Phase 2/3 clinical trial for locally advanced pancreatic cancer in Q2 2026, ensuring competitiveness and timely market entry in the oncology sector.
  • Innovative Therapy Potential: SIL204, designed as a next-generation RNA interference therapy targeting mutant KRAS oncogenes, has demonstrated significant anti-tumor activity in vitro, indicating its substantial potential in treating aggressive cancers.
  • Integrated Treatment Strategy: The company's approach combines both intratumoral and systemic administration, aiming to improve survival rates for patients suffering from high-mortality cancers that currently lack effective treatment options.
[object Object]
Preview
7.0
09-25Newsfilter
Silexion Therapeutics Meets Nasdaq Listing Standards Again

  • Regaining Compliance: Silexion Therapeutics has regained compliance with Nasdaq listing rules regarding minimum bid price and shareholders' equity, confirming a minimum bid price of $1.00 per share and $2.5 million in shareholders' equity.

  • Clinical Development Focus: The company is advancing towards Phase 2/3 clinical trials for its RNAi therapy SIL204, which has shown promising preclinical results in inhibiting KRAS-driven cancers, and is committed to developing innovative treatments for solid tumor cancers.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Silexion Therapeutics Corp (SLXN) stock price today?

The current price of SLXN is 3.167 USD — it has increased 15.16 % in the last trading day.

arrow icon

What is Silexion Therapeutics Corp (SLXN)'s business?

Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

arrow icon

What is the price predicton of SLXN Stock?

Wall Street analysts forecast SLXN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLXN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Silexion Therapeutics Corp (SLXN)'s revenue for the last quarter?

Silexion Therapeutics Corp revenue for the last quarter amounts to -3.29M USD, decreased -59.03 % YoY.

arrow icon

What is Silexion Therapeutics Corp (SLXN)'s earnings per share (EPS) for the last quarter?

Silexion Therapeutics Corp. EPS for the last quarter amounts to -2843000.00 USD, increased 6.52 % YoY.

arrow icon

What changes have occurred in the market's expectations for Silexion Therapeutics Corp (SLXN)'s fundamentals?

The market is revising No Change the revenue expectations for Silexion Therapeutics Corp (SLXN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -55.71%.
arrow icon

How many employees does Silexion Therapeutics Corp (SLXN). have?

Silexion Therapeutics Corp (SLXN) has 11 emplpoyees as of December 05 2025.

arrow icon

What is Silexion Therapeutics Corp (SLXN) market cap?

Today SLXN has the market capitalization of 9.90M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free